Since inhibitors of HDACs, GSK-3β, and TGF-β kinase have been applied against diseases including cancer and mental illness in clinic (Johnstone, 2002; Avila and Hernández, 2007; Ikushima and Miyazono, 2010), we further accessed the reprogramming-promoting efficiency of pharmaceutical compounds from these pathways. Here, GSK3B is linked to psychiatric disorder.